The National Cancer Research Institute (NCRI) is delighted to announce that Myeloma UK, a UK cancer research charity focussing exclusively on myeloma and related conditions, has recently joined NCRI as a Partner.

The COVID-19 pandemic has highlighted how collaborating towards a common goal can achieve great results. However, it has also impacted cancer research and the lives of cancer patients. It is more important than ever for cancer research funders to work together to continue to advance cancer research.

We are looking forward to having Myeloma UK working with us in the NCRI Partnership. Myeloma UK focuses on several areas that are aligned with NCRI’s fundamental principles and scientific priorities including early diagnosis and living with and beyond cancer.

Dr Iain Frame, CEO, NCRI

Myeloma UK develops new approaches to myeloma treatment through their biomedical research programme, including translational research projects and clinical trials.

As NCRI Partners, we are looking forward to being involved in discussions defining cancer research priorities and plans in the UK. By being involved in the Partnership, we can represent myeloma patients in these important discussions so that their needs are heard and considered.

Sarah McDonald, Director of Research, Myeloma UK

As Partners of NCRI, Myeloma UK will be able to share their expertise with other cancer research funders and learn from them. They will also make connections with other funders that can lead to exciting and innovative research collaborations to improve patient outcomes.

NCRI’s Partners include cancer research charities and funding bodies representing all four nations of the United Kingdom. NCRI Partners work together to coordinate their research and aim to avoid unnecessary duplication and maximise the impact of research for cancer patients and the public.